WO2000061141A3 - Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus - Google Patents

Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus Download PDF

Info

Publication number
WO2000061141A3
WO2000061141A3 PCT/US2000/009329 US0009329W WO0061141A3 WO 2000061141 A3 WO2000061141 A3 WO 2000061141A3 US 0009329 W US0009329 W US 0009329W WO 0061141 A3 WO0061141 A3 WO 0061141A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissues
therapeutic agents
methods
compositions
interior
Prior art date
Application number
PCT/US2000/009329
Other languages
English (en)
Other versions
WO2000061141A2 (fr
Inventor
Jessie L-S Au
Guillaume Wientjes
Original Assignee
Au Jessie L S
Guillaume Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Au Jessie L S, Guillaume Wientjes filed Critical Au Jessie L S
Priority to CA002369263A priority Critical patent/CA2369263A1/fr
Priority to AU42142/00A priority patent/AU777620B2/en
Priority to EP00921881A priority patent/EP1171118A2/fr
Priority to JP2000610474A priority patent/JP2003524624A/ja
Publication of WO2000061141A2 publication Critical patent/WO2000061141A2/fr
Publication of WO2000061141A3 publication Critical patent/WO2000061141A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne, au moins en partie, des méthodes qui améliorent la diffusion d'agents thérapeutiques, tels que des macromolécules ou des médicaments, à l'intérieur de tissus, tels que des tissus solides ou des tumeurs. La méthode utilise initialement un agent inducteur d'apoptose, tel que le paclitaxel, administré en doses propres à créer des canaux à l'intérieur du tissu et à y améliorer la pénétration d'agents thérapeutiques. Les méthodes classiques de traitement des tissus sont souvent peu efficaces parce que les agents thérapeutiques ne sont pas diffusés à l'intérieur du tissu. L'utilisation des méthodes et des compositions de l'invention permet de diffuser des agents thérapeutiques à l'intérieur du tissu.
PCT/US2000/009329 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus WO2000061141A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002369263A CA2369263A1 (fr) 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus
AU42142/00A AU777620B2 (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues
EP00921881A EP1171118A2 (fr) 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus
JP2000610474A JP2003524624A (ja) 1999-04-09 2000-04-07 治療薬の組織への送達を高める方法及び組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12867499P 1999-04-09 1999-04-09
US60/128,674 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061141A2 WO2000061141A2 (fr) 2000-10-19
WO2000061141A3 true WO2000061141A3 (fr) 2001-03-01

Family

ID=22436437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009329 WO2000061141A2 (fr) 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus

Country Status (5)

Country Link
EP (1) EP1171118A2 (fr)
JP (1) JP2003524624A (fr)
AU (1) AU777620B2 (fr)
CA (1) CA2369263A1 (fr)
WO (1) WO2000061141A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4778679B2 (ja) * 2001-10-03 2011-09-21 セレーター ファーマシューティカルズ インコーポレイテッド 併用薬剤を送達するための組成物
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (fr) 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
JP2004277379A (ja) * 2003-03-18 2004-10-07 Medicos Hirata:Kk 細胞死誘発ドラッグデリバリーシステム
CN102697737B (zh) * 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
WO2009116556A1 (fr) * 2008-03-19 2009-09-24 富士フイルム株式会社 Composition pharmaceutique pour injection
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
EP2481396A4 (fr) * 2009-09-21 2014-03-05 Jw Pharmaceutical Corp Nanoparticules d'oxaliplatine et leur procédé de préparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710134A (en) * 1994-05-20 1998-01-20 Behringwerke Aktiengesellschaft Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
WO1998032440A1 (fr) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit permettant d'inhiber le developpement de cancers; ce kit comprenant un agent chimiotherapeutique, un benzimidazole et facultativement un potentialisateur
JPH11269065A (ja) * 1998-03-19 1999-10-05 Microbial Chem Res Found 癌細胞のアポトーシス耐性の克服剤
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子ＮＦκＢ活性化阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641193A4 (fr) * 1992-05-20 1995-09-06 Daniel S Martin Combinaison de drogues chimiotherapeutiques.
US5932248A (en) * 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
ATE278397T1 (de) * 1997-03-31 2004-10-15 Boston Scient Ltd Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
DE69713526D1 (de) * 1997-06-20 2002-07-25 Baker Norton Pharma Lösliche prodrugs von paclitaxel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710134A (en) * 1994-05-20 1998-01-20 Behringwerke Aktiengesellschaft Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
WO1998032440A1 (fr) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit permettant d'inhiber le developpement de cancers; ce kit comprenant un agent chimiotherapeutique, un benzimidazole et facultativement un potentialisateur
JPH11269065A (ja) * 1998-03-19 1999-10-05 Microbial Chem Res Found 癌細胞のアポトーシス耐性の克服剤
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子ＮＦκＢ活性化阻害剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200008, Derwent World Patents Index; Class B02, AN 2000-090993, XP002150249 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 01 31 January 2000 (2000-01-31) *
See also references of EP1171118A2 *

Also Published As

Publication number Publication date
EP1171118A2 (fr) 2002-01-16
CA2369263A1 (fr) 2000-10-19
AU4214200A (en) 2000-11-14
AU777620B2 (en) 2004-10-21
WO2000061141A2 (fr) 2000-10-19
JP2003524624A (ja) 2003-08-19

Similar Documents

Publication Publication Date Title
WO2004093831A3 (fr) Combinaisons de vaccins cellulaires exprimant les cytokines
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
WO2001023405A3 (fr) Traitement therapeutique d'affections causees par le recepteur androgene
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2002041837A3 (fr) Traitement de mucosite
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
WO2005118601A3 (fr) Sulfonylethyle phosphorodiamidates
WO2000061141A3 (fr) Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus
WO2002058694A3 (fr) Procede de traitement de tumeurs et de cancers hematologiques
WO2006086693A3 (fr) Dispositifs medicaux
WO2002076548A3 (fr) Procedes et appareil pour le traitement d'un tissu malade
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
WO2004073375A8 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369263

Country of ref document: CA

Ref country code: CA

Ref document number: 2369263

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610474

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921881

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921881

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642